Emily Boxer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Emily Boxer has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Alissa R. Greenwald
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
1 shared publicationDaniel Kovarsky
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
1 shared publication- Dor Simkin
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
1 shared publication - Itay Tirosh
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
1 shared publication Lingling Zhang
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
1 shared publicationNisan Feigin
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
1 shared publication
Latest Publications
- Top Cited Papers
- 28 February 2025
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 22 (5) , 315-326
Emerging clinical applications of single-cell RNA sequencing in oncology
Single-cell RNA sequencing (scRNA-seq) has revolutionized our understanding of complex tissues both in health and in disease. Over the past decade, scRNA-seq has been applied to tumour samples obtained from patients with cancer in hundreds of studies, thereby advancing the view that each tumour is a complex ecosystem and uncovering the diverse states of both cancer cells and the tumour microenvironment. Such studies have primarily investigated and provided insights into the basic biology of cancer, although considerable research interest exists in leveraging these findings towards clinical applications. In this Review, we summarize the available data from scRNA-seq studies investigating samples from patients with cancer with a particular focus on findings that are of potential clinical relevance. We highlight four main research objectives of scRNA-seq studies and describe some of the most relevant findings towards such goals. We also describe the limitations of scRNA-seq, as well as future approaches in this field that are anticipated to further advance clinical applicability.
- 28 February 2025
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 22 (5) , 315-326
Top Cited PapersEmerging clinical applications of single-cell RNA sequencing in oncology
Single-cell RNA sequencing (scRNA-seq) has revolutionized our understanding of complex tissues both in health and in disease. Over the past decade, scRNA-seq has been applied to tumour samples obtained from patients with cancer in hundreds of studies, thereby advancing the view that each tumour is a complex ecosystem and uncovering the diverse states of both cancer cells and the tumour microenvironment. Such studies have primarily investigated and provided insights into the basic biology of cancer, although considerable research interest exists in leveraging these findings towards clinical applications. In this Review, we summarize the available data from scRNA-seq studies investigating samples from patients with cancer with a particular focus on findings that are of potential clinical relevance. We highlight four main research objectives of scRNA-seq studies and describe some of the most relevant findings towards such goals. We also describe the limitations of scRNA-seq, as well as future approaches in this field that are anticipated to further advance clinical applicability.